Shopping Cart
- Remove All
Your shopping cart is currently empty
ABT-869 is an innovative ATP-competitive inhibitor targeting all vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases (RTKs). Its hydrophilic metabolite, A-849529, contains carboxyl and amino groups.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
| Description | ABT-869 is an innovative ATP-competitive inhibitor targeting all vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases (RTKs). Its hydrophilic metabolite, A-849529, contains carboxyl and amino groups. |
| Synonyms | A849529, A 849529 |
| Molecular Weight | 405.38 |
| Formula | C21H16FN5O3 |
| Cas No. | 819058-88-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.